Cellular Reprogramming via Co-culture Bioreactor

Cell-specific immunoproliferative effects of human peripheral blood mononuclear cells (PBMCs) after exposure to mesenchymal stem cells (MSC), normal human dermal fibrosis (NHDF), liver hepatocellular carcinoma (Hep G2), and epithelial cells (EaHy296).


Invention Summary:

Co-culture systems can control for the interaction between diverse cell types. Specifically for cell therapy, co-culture cells can modulate the phenotype of a cell therapeutic during cell expansion. Current co-culture methods are not controlled or scalable. Furthermore, cocultures to expand and differentiate a cell therapy result in difficult downstream purification of the cell therapeutic population.

Researchers at Rutgers University developed a co-culture bioreactor system to modulate patient cells as a point-of-care technology platform. The co-culture cell population is physically separated but maintain dynamic and indirect interaction through genetic mediators. This controlled interaction leads to a cell therapy with a new phenotype. The technology can be scaled up for manufacturing and suitable for use at clinical locations.


Market Applications:

  • Cell manufacturing
  • Research tool
  • Blood Processing
  • Cell therapy

Advantages:

  • Ex vivo cell expansion
  • Use of patient’s cells minimizes immune response
  • Separation enables co-culture of patient cells with allogenic or xenogenic stimulator cells
  • Industrial scale-up
  • Simple cell recovery and purification
  • Dynamic co-culture with extended exposure times

Intellectual Property & Development Status:

Patent pending. Available for licensing and/or research collaboration.

Rutgers ID: 2018-056
Category(s):
Life Sciences
Contact:
Lisa Lyu
Licensing Manager
848-932-4539
lisa.lyu@rutgers.edu
Inventors:
Biju Parekkadan
Keywords: